Wex Pharmaceuticals Inc.   Report issue

For profit Phase 3
Founded: Vancouver BC Canada (1987)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2008
NCT00725114
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Wex Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

tetrodotoxin (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cancer Pain (Phase 3)

Neuralgia (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 1